Theragnostic Technologies was established in 2012 as a spin-off from Stony Brook University to develop a new efficient graphene-based MRI contrast agent that is safer and cheaper than current gadolinium-based agents.
The company unveiled its product, called ManGraDex, in June 2015. The ManGraDex needs to go through several clinical trial phases, and commercialization is planned for 2022 or 2023. Theragnostic is supported by the NIH Commercialization Accelerator Program.
Company Address
8 Windover Lane
Coram, NY 11727
United States
